Shares of Eli Lilly & Co. rose 3.38% to $1,062.19 Monday, on what proved to be an all-around grim trading session for the ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.

A major pharmaceutical company is making an announcement on Tuesday regarding growth of biopharma innovation in the Rocket ...

The pharmaceutical stock can still deliver.

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Expanding Lilly’s U.S. manufacturing presence in Alabama will boost the Huntsville economy. For every dollar Lilly invests ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.